APIDRA SOLOSTAR

LOE Approaching

insulin glulisine

BLASUBCUTANEOUSINJECTABLE
Approved
Apr 2004
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20

Mechanism of Action

analogs, including insulin glulisine. Insulins lower blood glucose by stimulating peripheral glucose uptake by skeletal muscle and fat, and by inhibiting hepatic glucose production. Insulins inhibit lipolysis and proteolysis and enhance protein synthesis.

Pharmacologic Class:

Insulin Analog

Clinical Trials (5)

NCT02910518Phase 1Completed

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Started Feb 2017
44 enrolled
Type1 Diabetes Mellitus
NCT02914886Phase 4Completed

Beneficial Effect of Insulin Glulisine by Lipoatrophy and Type 1 Diabetes (LAS)

Started Sep 2016
14 enrolled
Type 1 DiabetesLipoatrophy
NCT01662921Phase 2Completed

Comparator Trial Using Insulin Glulisine vs. Insulin Lispro for Treatment of Gestational Diabetes

Started Apr 2013
17 enrolled
Diabetes During Pregnancy
NCT01768559Phase 3Completed

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

Started Jan 2013
894 enrolled
Type 2 Diabetes
NCT01203111Phase 4Completed

Intensive Insulin Glulisine Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Basal Insulin and Oral Glucose-lowering Drugs

Started Dec 2010
207 enrolled
Diabetes Mellitus, Type 2